Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC disclosures for an early-stage biotech can feel like a dense immunology textbook. Jasper Therapeutics’ filings are no exception—its 10-K hides nuanced trial-failure risks, while 8-Ks rush out material updates on JSP191 dose cohorts. Stock Titan offers Jasper Therapeutics SEC filings explained simply, so you can stop combing through pages of FDA terminology.
Our AI reads every Jasper Therapeutics quarterly earnings report 10-Q filing, highlights cash-runway shifts, and translates manufacturing updates into plain English. Curious about Jasper Therapeutics insider trading Form 4 transactions? We stream alerts the instant they hit EDGAR, delivering Jasper Therapeutics Form 4 insider transactions real-time. Need the latest Jasper Therapeutics proxy statement executive compensation? Summaries pinpoint option awards and performance goals. From pipeline milestones to new financing terms, each document arrives minutes after filing—already parsed by AI.
Here’s what you can explore today:
- Jasper Therapeutics annual report 10-K simplified—see clinical development risks, R&D spend, and partnership revenue potential.
- Jasper Therapeutics quarterly earnings report 10-Q filing analysis—track cash burn against upcoming Phase 1/2 studies.
- Jasper Therapeutics Form 4 insider transactions real-time—monitor executive stock moves before data readouts.
- Jasper Therapeutics 8-K material events explained—decode trial pauses, funding rounds, or leadership changes.
Whether you ask, “How do I read Jasper Therapeutics’ 10-K?” or “Where can I find Jasper Therapeutics executive stock transactions Form 4?,” our platform delivers. Start understanding Jasper Therapeutics SEC documents with AI and make smarter biotech decisions in minutes.
Kingdon Capital Management, L.L.C. and its founder Mark Kingdon have filed a Schedule 13G with the U.S. SEC disclosing a passive ownership position in Jasper Therapeutics, Inc. (NASDAQ: JSPR).
- Shares owned: 765,000 voting common shares.
- Ownership percentage: 5.1% of Jasper’s outstanding common stock.
- Voting & dispositive power: Both reporting persons hold shared voting and dispositive power over all reported shares; no sole voting or dispositive authority.
- Date of event: 03 July 2025; filing signed 11 July 2025.
- Filing basis: Schedule 13G indicates the stake is for investment purposes only and is not intended to influence control of the issuer.
- Reporting persons: • Kingdon Capital Management, L.L.C. – Delaware investment adviser (Type IA). • Mark Kingdon – U.S. individual (Type HC, IN). All securities are held on behalf of advisory clients of Kingdon Capital.
- Certification: Both filers certify the shares were “not acquired and are not held for the purpose of changing or influencing control.”
This disclosure places Kingdon Capital among Jasper’s significant shareholders, crossing the 5% reporting threshold and potentially increasing institutional visibility in the stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) filed a Form 8-K dated July 7, 2025 to disclose a material corporate event under Item 8.01.
The company issued a press release (Exhibit 99.1) announcing updated data from its BEACON Phase 1b/2a study evaluating subcutaneous briquilimab in adults with chronic spontaneous urticaria. Jasper will host a conference call and webinar on July 7, 2025 at 8:30 a.m. EDT to discuss the new findings and provide a program update. A supporting investor presentation is furnished as Exhibit 99.2. No financial statements or earnings figures accompany this filing.
Key administrative details include the trading symbols JSPR (common stock) and JSPRW (warrants), and confirmation of listing on The Nasdaq Stock Market LLC. The filing contains customary signatures and an iXBRL cover page file (Exhibit 104).
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
